Guretolimod

Guretolimod

SCHEMBL16616711

CCCC(CCO)Nc1nc(N)nc(C)c1Cc1ccc(CN(CC(=O)O)CC(F)(F)F)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 16/20 1.00
TLR8 Q9NR97 6/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guretolimod SCHEMBL15392137 1.00 TLR7 (1.00) TLR7TLR8
SCHEMBL29447484 0.93 TLR7 (0.87) TLR7TLR8
SCHEMBL16624340 0.93 TLR7 (0.87) TLR7TLR8
SCHEMBL20936318 0.93 TLR7 (0.87) TLR7TLR8
SCHEMBL15393115 0.92 TLR7 (1.00) TLR7TLR8
SCHEMBL15393191 0.92 TLR7 (1.00) TLR7TLR8
SCHEMBL16617093 0.92 TLR7 (0.85) TLR7TLR8
SCHEMBL29811247 0.92 TLR7 (0.85) TLR7TLR8
SCHEMBL16617095 0.92 TLR7 (0.85) TLR7TLR8
SCHEMBL16624385 0.91 TLR7 (0.84) TLR7TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12226480-B2 Combination drug including TLR7 agonist Sumitomo Pharma Co., Ltd. (JP) 2025-02-18 US claimed
US-12077510-B2 Carboxylic acid compounds Sumitomo Pharma Co., Ltd. (JP) 2024-09-03 US claimed
US-20220267282-A1 CARBOXYLIC ACID COMPOUNDS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-08-25 US claimed
US-11299465-B2 Carboxylic acid compounds SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-04-12 US claimed
US-20210170022-A1 COMBINATION DRUG INCLUDING TLR7 AGONIST Sumitomo Pharma Co., Ltd. (JP) 2021-06-10 US claimed
EP-3730152-A1 COMBINATION DRUG INCLUDING TLR7 AGONIST Sumitomo Dainippon Pharma Co., Ltd. (JP) 2020-10-28 EP claimed
US-20200317623-A1 CARBOXYLIC ACID COMPOUNDS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-10-08 US claimed
EP-2850067-B1 CARBOXYLIC ACID COMPOUNDS SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2017-08-16 EP claimed
US-9376398-B2 Carboxylic acid compounds SUMITOMO DAINIPPON PHARMA CO., LTD (JP) 2016-06-28 US claimed
US-12226480-B2 Combination drug including TLR7 agonist Sumitomo Pharma Co., Ltd. (JP) 2025-02-18 US disclosed
US-12077510-B2 Carboxylic acid compounds Sumitomo Pharma Co., Ltd. (JP) 2024-09-03 US disclosed
US-20220267282-A1 CARBOXYLIC ACID COMPOUNDS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-08-25 US disclosed
US-11299465-B2 Carboxylic acid compounds SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-04-12 US disclosed
US-11299465-B2 Carboxylic acid compounds SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-04-12 US disclosed
US-20190119220-A1 CARBOXYLIC ACID COMPOUNDS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-04-25 US disclosed
US-10150743-B2 Carboxylic acid compounds SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-12-11 US disclosed
EP-2850067-B1 CARBOXYLIC ACID COMPOUNDS SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2017-08-16 EP disclosed
US-20160251319-A1 CARBOXYLIC ACID COMPOUNDS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2016-09-01 US disclosed
US-9376398-B2 Carboxylic acid compounds SUMITOMO DAINIPPON PHARMA CO., LTD (JP) 2016-06-28 US disclosed
US-20150099770-A1 CARBOXYLIC ACID COMPOUNDS Sumitomo Pharma Co., Ltd. (JP) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099770-A1 CARBOXYLIC ACID COMPOUNDS C9, SUCNR1, C3AR1 TLR7 87/4885TLR8 665/4885
US-20160251319-A1 CARBOXYLIC ACID COMPOUNDS C9, SUCNR1, C3AR1 TLR7 87/4885TLR8 665/4885
US-10150743-B2 Carboxylic acid compounds C9, C3AR1, SUCNR1 TLR7 79/4885TLR8 566/4885
US-12077510-B2 Carboxylic acid compounds C9, C3AR1, SUCNR1 TLR7 79/4885TLR8 566/4885
US-20200317623-A1 CARBOXYLIC ACID COMPOUNDS C9, C3AR1, SUCNR1 TLR7 79/4885TLR8 566/4885
US-20190119220-A1 CARBOXYLIC ACID COMPOUNDS C9, C3AR1, SUCNR1 TLR7 79/4885TLR8 566/4885
US-11299465-B2 Carboxylic acid compounds C9, C3AR1, SUCNR1 TLR7 79/4885TLR8 566/4885
US-12226480-B2 Combination drug including TLR7 agonist TLR7, TLR9, CD274 TLR7 1/4885TLR8 8/4885
US-20210170022-A1 COMBINATION DRUG INCLUDING TLR7 AGONIST TLR7, TLR9, CD274 TLR7 1/4885TLR8 8/4885
US-20220267282-A1 CARBOXYLIC ACID COMPOUNDS C9, C3AR1, SUCNR1 TLR7 79/4885TLR8 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.